Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Integra Lifesciences Holdings (IART) EBIAT (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EBIAT for 17 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 108.77% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$516.5 million through Dec 2025, down 7338.77% year-over-year, with the annual reading at -$516.5 million for FY2025, 7337.7% down from the prior year.
  • EBIAT hit -$1.7 million in Q4 2025 for Integra Lifesciences Holdings, up from -$5.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $52.9 million in Q4 2022 to a low of -$484.1 million in Q2 2025.
  • Historically, EBIAT has averaged -$5.3 million across 5 years, with a median of $19.7 million in 2023.
  • Biggest five-year swings in EBIAT: surged 9603.52% in 2021 and later tumbled 3803.18% in 2025.
  • Year by year, EBIAT stood at $45.4 million in 2021, then grew by 16.66% to $52.9 million in 2022, then plummeted by 62.54% to $19.8 million in 2023, then dropped by 2.01% to $19.4 million in 2024, then tumbled by 108.77% to -$1.7 million in 2025.
  • Business Quant data shows EBIAT for IART at -$1.7 million in Q4 2025, -$5.4 million in Q3 2025, and -$484.1 million in Q2 2025.